Intuitive Surgical, Inc. (ISRG) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates in one reportable segment, managing its business on a consolidated basis. As of June 30, 2025, the company had an installed base of approximately 10,488 da Vinci systems and 905 Ion systems.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $2,440.0 | $2,009.9 | $4,693.4 | $3,900.5 |
| Gross Profit | $1,617.9 | $1,372.7 | $3,075.6 | $2,618.1 |
| Gross Margin | 66.3% | 68.3% | 65.5% | 67.1% |
| Operating Income | $743.4 | $567.3 | $1,321.5 | $1,036.7 |
| Net Income (Attributable to ISRG) | $658.4 | $526.9 | $1,356.8 | $1,071.8 |
| Diluted EPS | $1.81 | $1.46 | $3.72 | $2.97 |
| Operating Cash Flow (YTD) | $1,297.0 | $885.9 | - | - |
| Cash & Investments | $9,532.5 | - | - | - |
Note: Cash and investments balance of $9.53 billion is as of June 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 21% in Q2 2025 and 20% YTD, driven by 18% growth in instruments and accessories and 28% growth in systems revenue.
- Procedure Volume: da Vinci procedures grew 17% in Q2 2025 (approx. 775,000 procedures), with U.S. growth of 14% and Outside U.S. (OUS) growth of 23%. Ion procedures grew 52% in Q2 2025.
- System Placements: 395 da Vinci systems were placed in Q2 2025 (up from 341 in Q2 2024), including 180 da Vinci 5 systems. Ion placements decreased to 54 from 74.
- Margin Compression: Gross margin decreased to 66.3% from 68.3% in the prior year quarter. This was primarily due to higher costs associated with the phased launch of the da Vinci 5 system, new tariffs, and incremental fixed overhead costs.
- Share Repurchases: The company repurchased 0.3 million shares for $181.0 million in Q2 2025. Approximately $3.8 billion remains authorized under the repurchase program.
Guidance, Outlook, and Risks
- Tariff Impact: Management anticipates a significant increase in cost of revenues for the second half of 2025 due to U.S. tariffs on imports from Mexico, Canada, China, and other countries. This is expected to impact results of operations.
- Product Launch: The company is in a phased launch of the da Vinci 5 surgical system, which includes force feedback technology. Demand for this next-generation system is driving system placements and ASPs.
- Regulatory Environment: The company obtained European certification for the da Vinci 5 in July 2025 and regulatory clearance in Japan in June 2025. In China, sales are subject to government quotas and pricing pressures.
- Legal Contingencies: The company faces ongoing product liability lawsuits and antitrust litigation (e.g., Surgical Instrument Service Company, Inc. and class actions regarding instrument repair). While the company disputes allegations, outcomes are uncertain and could materially affect financial results.
- Capital Expenditures: Expected to range between $650 million and $725 million in 2025, primarily for facilities to expand manufacturing capacity.
Key Facts for Investor Verification
- Tariff Exposure: Verify the specific impact of new U.S. tariffs on raw materials and finished goods, particularly regarding manufacturing in Mexico and imports from China and Germany.
- da Vinci 5 Adoption: Monitor the rate of trade-ins of fourth-generation systems for the da Vinci 5 and the associated impact on revenue recognition and margins.
- China Market Dynamics: Assess the impact of domestic competition and government pricing limits on procedure volume and revenue in China.
- Legal Outcomes: Track developments in the antitrust class action litigation regarding instrument repair and the product liability cases with trial dates in the next 12 months.
- Inventory Levels: Review the $1.67 billion inventory balance, which increased significantly to mitigate supply chain risks and support the leasing business expansion.